Consequently, a phase II trial examined the efficacy of pembrolizumab according to the MMR profile in patients with colorectal cancer, demonstrating that the ORR and the immune-related PFS rate at 20 weeks in MMR-deficient patients and MMR-proficient patients were 40% vs. 0% and 78% vs. 11%, respectively [59]. The gene discussed is MRC1; the disease is colorectal cancer.